Needham & Company downgraded Pacira Pharmaceuticals (NASDAQ: PCRX) from Buy to Hold.Analyst Serge Belanger commented, "The FDA's briefing documents presaged ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE